Content PART I: ANDA Roadmap PART II: Understanding of CPPs & CQAs PART III: Scale-Up and Technology Transfer PART IV: Process Validation & Sampling 2
|
|
- Barbra Booker
- 5 years ago
- Views:
Transcription
1 EMA, FDA- ANDA Readiness -OSD Generics Solution Post Formulation Development Horch Guo, May. 2016, Changzhou, China
2 Content PART I: ANDA Roadmap PART II: Understanding of CPPs & CQAs PART III: Scale-Up and Technology Transfer PART IV: Process Validation & Sampling 2
3 PART I: ANDA Roadmap 3
4 ANDA Product Development Roadmap - QbD based 1 Market Survey & Kick-off 2 Pre- Formulation 3 Formulation Development 4 Process Dev. & Scale-UP 5 Exhibit batches(pv) 6 ANDA Filing -Raw Materials -QTPP -Raw Materials Audit -Equip. Qualification -PV Protocol -Mfg. & Ana Equip. -Mfg Rooms -Containments -CQAs -CMAs -Method of Mfg.Dev. -CV Method Develop. -Tooling -CPPs & CQAs -Method of Mfg. (IPC,Sampling) Dev. -Method of Mfg. (IPC,Sampling) -Method of Pkg. -CV -Process Varialbes & Range -Method of Pkg. Dev. -Scale-UP -CV Protocol 4
5 QTPP & & CQA & CPPs 5
6 PART II: CPPs & CQAs 6
7 Quality Right at First Time -QbD - QbD Concept Product Knowledge Process Understanding Product Specification Product Quality Attributes Process Parameters Process Controls Product Performance Product Design Process Design Process Performance -Desired Clinical Performance -Dosage Form -Excipients -Stability -Unit Operations -Control Strategy -Cpk -Robustness 7
8 Quality Right at First Time - Patient based integrated RA (Q8, Q9, Q10) ICH Q8/9/10- Patient based risk assessment QMS: ISO 9001:2005 8
9 Quality Right at First Time - Design Space & Robustness Quality issue & Cost Design Parameter Design Space Operation Range Design Space Knowledge Space 9
10 Quality Right at First Time - Operation / Design Space & Robustness Critical Process Parameter (CPP) A process input that must be kept within a proven acceptable range (PAR) in order to ensure that the final product will be within its CQA limits Process Understanding Critical Quality Attribute (CQA) a process output which is critical to achieving the product quality/safety/efficacy (e.g. impurity profile, stability, dissolution) Robust Process Normal Operating Range (NOR) Non-Robust Process Normal Operating Range (NOR) Proven Acceptable Range (PAR) Proven Acceptable Range (PAR)
11 Quality Right at First Time -Operation Process/ Reliable & Robust Risk Assessments (FMEA) -The Variability on CPPs Critical Process Parameter (CPP) -Intrinsic API properties (solubility, stability) -Formulation Principle -Manufacturing Costs -Volume considerations Technology -Wet Granulation -Dry Granulation -Extrusion Process Design -Define the CPPs and PARs Process Control Strategy -Control Range
12 Quality Right at First Time -Operation/ Variations Control key points People Equipment/Utilities Environment Materials Profile & education Adequate design Zone concept Specifications Job description Measurement systems containment Supplier management Regular training Specifications Layout Packaging Supervision Qualification Hygiene Storage/transport Communication Calibration Microbiology monitoring Testing Procedures Maintenance Pest control Rewarding Cleaning Unknown variations are the major threat for Quality ( We do not know what we do not know )
13 OSD -Operation & PPs & QAs Operation Process Parameter Quality Attributes Milling Wet granulation -Mill type -Speed -Blade configuration/type -Screen type and size -Feed rate High Shear Granulation -Pre-binder mixing time -Impeller speed/configuration/location -Chopper speed/configuration -Spray nozzle type/location -Method of binder addition -Binder fluid temperature -Binder addition rate/time -Post-granulation mix/kneading time -Bowl/product temperature -Power consumption (kw) -Particle size distribution -Particle shape -Bulk/tapped density -Flow properties -Polymorphic form -Moisture content -Flow property -Particle size and distribution -Granule size and distribution -Bulk density Wet granulation 13 Fluid Bed Granulation -Mixing time -Spray nozzle type/number/pattern/configuration -Method of binder addition -Binder fluid temperature -Binder fluid addition rate/time -Inlet airflow, temperature, volume and dew point -Exhaust air temperature and flow rate -Filter property and size -Filter shaking intervals -Product temperature -Moisture content -Flow property -Particle size and distribution -Granule size and distribution -Bulk density
14 OSD-Operation & PPs & QAs Operation Process Parameter Quality Attributes Drying Fluid Bed Dryer -Inlet air volume, temperature, and dew point -Exhaust air temperature and flow -Filter properties -Filter shaking intervals -Product temperature -Total drying time -Granule size and distribution -Granule strength and uniformity -Particle size -Flow -Bulk/tapped density -Moisture content -Residual solvents Drying Mixing Tray Dryer -Number of carts and trays per chamber -Amount of product per tray -Drying time and temperature -Airflow -Inlet air dew point -Vacuum/microwave dryer -Jacket temperature -Condenser temperature -Impeller speed -Vacuum strength -Microwave frequency -Electric field -Energy supplied -Product temperature -Type and geometry of mixer -Order of addition -Mixer load level -Time of rotations -Holding time for final blend -Granule size and distribution -Granule strength and uniformity -Particle size -Flow -Bulk/tapped density -Moisture content -Residual solvents -Blend uniformity -Particle size distribution -Bulk/tapped density -Moisture content -Flow properties 14
15 OSD -Operation & PPs & QAs Operation Process Parameter Quality Attributes Dry Granulation -Roller type -Roll speed -Gap setting -Roll pressure force -Temperature -Roller gap -Auger screw rate -Appearance -Ribbon/particle size and shape -Ribbon density, strength, and thickness -Moisture content Compression Coating -Compression speed and force -Precompression force -Feed frame type and speed -Hopper design, height, and vibration -Tablet weight and thickness -Depth of fill -Punch penetration depth -Total pre-heating time -Spray nozzle type/number/pattern/configuration -Individual gun spray rate -Total spray rate -Pan rotation speed -Atomization air pressure -Pattern air pressure -Inlet airflow, temperature, and dew point -Exhaust air temperature and airflow -Product temperature -Total coating time -Target tablet weight -Weight uniformity -Content uniformity -Hardness -Thickness -Tablet porosity -Friability -Visual attributes - -Weight of core tablets -Appearance -Visual attributes -% Weight gain -Film thickness -Color uniformity -Hardness -Thickness -Friability 15
16 PART III: Scale-Up and Technology Transfer 16
17 Scale-Up & Technology Transfer 17
18 Scale-Up Wet Granulation CQAs related -Flow property -Particle size and distribution -Granule size and distribution -Bulk density -API & Excipients ratio -Binding solution properties CPPs related 18
19 Scale-Up Dry Granulation CQAs related -Particle size & Particle size distribution -Particle flowability -Particle shape -API & excipients ratio CPPs related Scale Batch Size(Kg) Roller width (mm) Roller diameter (mm) Roller gap (mm) Roller pressure (bar) Mill Screen orifice size (mm) Lab Pilot Commercial
20 Scale-Up Blending & Lubrication Scale Batch Size(Kg) Blender Capacity (L) CQAs related -Particle size & Particle size distribution -Particle flowability -Particle shape -API & excipients ratio Volume Fill Level (%) Rotation Speed (rpm) Final Blending (min) Lubrication (min) Lab Pilot Commercial CPPs related 20
21 Scale-Up Coating 21
22 PART IV: Process Validation & Sampling 22
23 PV Lifecycle 制 业 药 23
24 CPP & CQA & PV -Quality Risk Management 24
25 PV-Quality Risk Management A successful validation program depends on information and knowledge from product and process development 25
26 PV -Deliverables 26
27 PV Sampling plan e.g. Blending Step Sampling Test Sample a minimum of 10 locations distributed throughout the mixer/blender at three different levels (top, middle and bottom). Assay (potency) In-process controls Holding time Sample size should not be greater than three times (3X) the weight of the dosage unit. Sample quantities larger than 3X can be used if they can be scientifically justified. Composite sample 27
28 Cleaning -Validation phase- Cleaning Validation Evaluation on the critical points for the equipment selection and design 3 continuous CV for campaign production CV Sampling Identify Product & Process contacted surface area and risk evaluation Develop the equipment based cleaning recipe and CVP QC analysis Cleaning Validation Master Plan Develop and validate the analysis method (API residual and recovery testing) Cleaning Validation Report 28 -Cleaning Validation team with early involvement is most important for cleaning & cross-contamination!
29 More information... Authorities:
30 30
31 Thanks for your attention! 31
Quality by Design (QbD)
Evaluating the Critical Quality attributes & Critical Process Parameters-A Case Study-Tablets GMP International Workshop February 20/21, 2008 Mumbai, India Mukund Yelvigi Director, Therapeutic Area Management,
More informationA Framework and Case Study for Implementing the New Process Validation Guidance
A Framework and Case Study for Implementing the New Process Validation Guidance Presented By Bikash Chatterjee President and Chief Technology Officer Pharmatech Associates Agenda Introduction Comparing
More informationStage 3 - Process Validation: Measuring what matters
Stage 3 - Process Validation: Measuring what matters Trevor Schoerie - PharmOut A quote. The company that fails is the company that comes to us and says Just tell us what to do and we will do it. The company
More informationHow to Identify Critical Quality Attributes and Critical Process Parameters
How to Identify Critical Quality Attributes and Critical Process Parameters Jennifer Maguire, Ph.D. Daniel Peng, Ph.D. Office of Process and Facility (OPF) OPQ/CDER/FDA FDA/PQRI 2 nd Conference North Bethesda,
More informationApplied Process Understanding in Drug Product Development
Applied Process Understanding in Drug Product Development A combined pharmaceutical science, materials science and chemical process engineering approach 17 October, Heidelberg, Germany ir Sander van den
More informationImplementing Quality by Design Principles and Concepts to Drug Delivery and Formulation Development. S Betterman 15Apr2015
Implementing Quality by Design Principles and Concepts to Drug Delivery and Formulation Development S Betterman 15Apr2015 Agenda Background Implementation Strategy Infrastructure Building Project Application
More informationQuality by Design, Revolution or Evolution? Wim Oostra
Quality by Design, Revolution or Evolution? Wim Oostra 1993 1998 2007 2009 2013 And many more.. Content Introduction A bit of history Examples A New product Legacy product Today? The triggers The goal
More informationPAT in Action: A Lifecycle Approach to Applied Process Understanding to set meaningful process and product specifications October, Heidelberg, Germany
PAT in Action: A Lifecycle Approach to Applied Process Understanding to set meaningful process and product specifications October, Heidelberg, Germany ir Sander van den Ban, CEng The Unpredictability of
More informationQbD implementation in Generic Industry: Overview and Case-Study
QbD implementation in Generic Industry: Overview and Case-Study Inna Ben-Anat, QbD Strategy Leader, Teva Pharmaceuticals IFPAC JAN 2013 R&D Three Core Components of QbD and Generic Industry: How Do They
More informationControl Strategy. Implementation of ICH Q8, Q9, Q10
Implementation of ICH Q8, Q9, Q10 Control Strategy International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use Introduction Structure of this session
More informationRoller Compaction: New trends, challenges and solutions
Roller Compaction: New trends, challenges and solutions TODD STUTZMAN, PHARM.D. R.PH. DIRECTOR, PHARMACEUTICS SARAH PYSZCZYNSKI, PH.D. PRINCIPAL SCIENTIST 21FEB2017 2017 Catalent Pharma Solutions. All
More informationDr. Sheelpriya walde Professor Gurunanak college of pharmacy, Nagpur
Dr. Sheelpriya walde Professor Gurunanak college of pharmacy, Nagpur GMP ( Adopted in 1975 ) In India Good manufacturing practices are the practices required in order to conform to guidelines recommended
More informationICH Q9 An Industry Perspective: Ensuring Quality to Patients in a Risk-Based Regulatory Environment
ICH Q9 An Industry Perspective: Ensuring Quality to Patients in a Risk-Based Regulatory Environment Thomas Schultz, Ph.D. Director, Regulatory Sciences Johnson & Johnson September 12, 2007 Presentation
More informationBetter wet granulation: development, scale-up and manufacture
Better wet granulation: development, scale-up and manufacture By Tim Freeman, Freeman Technology Wet granulation is a common unit operation in the pharmaceutical industry yet accurate endpoint detection
More informationSUPAC IR/MR Update. Glenn Van Buskirk, Ph.D. PQRI Lead Author April 2013
SUPAC IR/MR Update Glenn Van Buskirk, Ph.D. PQRI Lead Author April 2013 Why do it? SUPAC IR/MR Update Oral solid dosage forms continue to be the most significant class of drug product submissions to FDA
More informationContinuous Manufacturing
Continuous Manufacturing Continuous ing in the Industry Continuous processing has been adopted by the majority of process industries for the manufacturing of fluids (i.e. liquids and gasses) and solids
More informationA Comprehensive Review on Quality by Design (QbD) in Pharmaceuticals
Review Article Hardik Patel* 1, Shraddha Parmar 1, Bhavna Patel 1 1 Post Graduate Department of Pharmaceutical Sciences, Sardar Patel University, Vallabh Vidyanagar, Gujarat, India. *Corresponding author
More informationSakura Bloom Tablets P2 Mock
Sakura Bloom Tablets P2 Mock Mock P2 English version Sakura Bloom Tablets Disclaimer This mock provides an example of the contents to be included in CTD 2.3.P.2 Pharmaceutical Development section for a
More informationBasic Aspects of Process Validation of Solid Oral Dosage Forms
Review Article Basic Aspects of Process Validation of Solid Oral Dosage Forms Sharma Tejal Department of Pharmaceutics, B. N. Girls College of Pharmacy, Udaipur (Raj.) 313002(India) Validation of the manufacturing
More informationQuality by design: A holistic concept of building quality in pharmaceuticals
Available online at www.pharmscidirect.com Int J Pharm Biomed Res 2012, 3(2), 100-108 Review article International Journal of PHARMACEUTICAL AND BIOMEDICAL RESEARCH ISSN No: 0976-0350 Quality by design:
More informationApplication of Quality by Design (QbD) in product development. James E. Polli September 16, 2015
Application of Quality by Design (QbD) in product development James E. Polli jpolli@rx.umaryland.edu September 16, 2015 Pharmaceutical Equivalence Same active ingredient(s) Same dosage form Same route
More informationContinuous Processing. MODCOS for Continuous Oral Solid Dosage Production Textmasterformat in Mastervorlage eingeben
Continuous Processing MODCOS for Continuous Oral Solid Dosage Production 1 Why continuous production 2 Why Continuous Production? Saving manufacturing costs High productivity because of substantial time
More informationCHALLENGES & OPPORTUNITIES OF ICHQ8 (PHARMACEUTICAL DEVELOPMENT) AN INDUSTRY PERSPECTIVE
CHALLENGES & OPPORTUNITIES OF ICHQ8 (PHARMACEUTICAL DEVELOPMENT) AN INDUSTRY PERSPECTIVE Paul Stott, PhD Head of US Product Development AstraZeneca ICH Quality Guidelines Workshop BioKorea 2007 Sept 13-14
More informationValidation of Pharmaceutical Manufacturing Process Focus: APIs.
Validation of Pharmaceutical Manufacturing Process Focus: APIs Validations: Regulatory History (US FDA) Sterilisation 1977 Aseptic processing 1979 Water Systems 1981 Non-sterile Mfg Process 1987 Revised
More informationMeeting Solid Dose Formulation Challenges
Streamlining (Fast Tracking) Solid Dosage Form Development Tony Carpanzano, B.S., R. Ph. Director, Research & Development Streamlining (Fast Tracking) Solid Dosage Form Development Meeting Solid Dose Formulation
More informationMaximizing Roller Compaction Benefits with Proper Excipient Selection
A sponsored whitepaper. Maximizing Roller Compaction Benefits with Proper Excipient Selection By: Bernhard Fussnegger, Global Development and Technical Marketing, PVP/Coatings, Instant & Modified Release,
More informationRegulatory Assessment
Implementation of ICH Q8, Q9, Q10 Regulatory Assessment International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use Presentation Overview Goal
More informationDeveloping new drug products is very expensive, especially
As appeared in March 2018 Tablets & Capsules www.tabletscapsules.com formulation Developing fixed-dose combinations Amar Patel, Bruhalkumar Shah, Deep Patel, Satish Shetty, and Anthony Qu Halo Pharmaceuticals
More informationUniversity of Sulaimani College of Pharmacy Dept. of Pharmaceutics 5 th stage Second Semester
University of Sulaimani College of Pharmacy Dept. of Pharmaceutics 5 th stage Second Semester 2/26/2018 Industrial Pharmacy II, Dr. rer. nat. Rebaz Ali 1 Outlines Powder flow Introduction Factor affecting
More informationInspection. Implementation of ICH Q8, Q9, Q10
Implementation of ICH Q8, Q9, Q10 International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use Outline Aim of - as a key part of the regulatory
More informationShort review on Quality by design: A new Era of Pharmaceutical drug development
International Journal of Drug Development & Research July-September 2012 Vol. 4 Issue 3 ISSN 0975-9344 Available online http://www.ijddr.in Covered in Official Product of Elsevier, The Netherlands SJR
More informationTablet formulation design spaces for direct compression and roller compaction. QbD in Pharmaceutical Development: processes
QbD in Pharmaceutical Development: Tablet formulation design spaces for direct compression and roller compaction processes Morten Allesø, PhD (MSc Pharm) Pharmaceutical scientist ISPE Nordic PAT CoP, June
More informationConducting Supplier Audits: Ensure Validation Compliance
Conducting Supplier Audits: Ensure Validation Compliance Presented by: Gamal Amer, Ph. D. Principal Premier Compliance Services, Inc. All rights reserved. Do not copy without permission. 1 Outline Why
More informationScientific and Regulatory challenges in Quality by Design (QbD) submissions
Health Santé Canada Canada Scientific and Regulatory challenges in Quality by Design (QbD) submissions Krishnan R. Tirunellai, Ph. D. Bureau of Pharmaceutical Sciences TPD, Health Canada CVG, October 2007
More informationAvailable through Online
ISSN: 0975-766X CODEN: IJPTFI Available through Online Review Article www.ijptonline.com PROCESS VALIDATION OF CRITICAL STEPS INVOLVED IN MANUFACTURING OF SOLID DOSAGE FORMS IN PHARMACEUTICAL INDUSTRY
More informationProcess Design Risk Management A Proactive Approach
Page 1 of 7 Guest Column August 30, 2017 Process Design & Risk Management A Proactive Approach By Sandra Wassink, Principal Process Engineer, Pharmatech Associates The FDA has given us the green light
More informationOptimization of a Continuous Wet Granulation Process by Understanding Granule Properties
Optimization of a Continuous Wet Granulation Process by Understanding Granule Properties Presented By Andrew Birkmire Process Development Manager GEA Process Engineering Presentation Outline Description
More informationQbD QUANTITATIVE MEASUREMENTS OF CQAS IN SOLID DOSAGE FORM UNIT OPERATIONS
QbD QUANTITATIVE MEASUREMENTS OF CQAS IN SOLID DOSAGE FORM UNIT OPERATIONS Porosity Density Surface Area USP USP USP Porosimetry by Mercury Intrusion Density of Solids - Gas Pycnometry
More informationInt. J. Pharm. Sci. Rev. Res., 34(1), September October 2015; Article No. 23, Pages: Process Validation of Tablet Dosage Form in Industries
Review Article Process Validation of Tablet Dosage Form in Industries Ram Mohan S.R, N. Vishal Gupta* Pharmaceutical Quality Assurance group, Dept of Pharmaceutics, JSS University, Sri ShivarathreeshwaraNagara,
More informationAchieving Excellence in Continuous Manufacturing: Using Process Models for Process Development and Understanding Process Dynamics
Achieving Excellence in Continuous Manufacturing: Using Process Models for Process Development and Understanding Process Dynamics By Fernando Muzzio, Marianthi Ierapetritou, Rohit Ramachandran, Amanda
More informationWHO DRAFT PHARMACEUTICAL DEVELOPMENT FOR MULTISOURCE (GENERIC) PHARMACEUTICAL PRODUCTS
23 April 2008 Quality Assurance Programme Quality Assurance and Safety: Medicines (QSM) Department of Medicines Policy and Standards (PSM) World Health Organization CH-1211 Geneva 27 Switzerland WHO DRAFT
More informationcoating Layering an API onto tablets using a perforated-drum coater: A case study ACG Pharma Technologies
As appeared in Tablets & Capsules April 201 coating www.tabletscapsules.com Layering an API onto tablets using a perforated-drum coater: A case study Vasant Shetty, Sameer Borate, Anuprita Landge, and
More informationNIRS, PAT, RTR testing EU experience and regulatory perspective
NIRS, PAT, RTR testing EU experience and regulatory perspective Heidelberg, Germany October 2013 European Compliance Academy (ECA) Overview of the presentation General considerations Cases submitted in
More information2nd FDA/PQRI Conference on Advancing Product Quality
2nd FDA/PQRI Conference on Advancing Product Quality Generic Pharma Perspective on the Identification of Critical Quality Attributes and Critical Process Parameters Bruce D. Johnson, Ph.D. Vice President
More informationA Review on Process Validation of Pharmaceutical Manufacturing Processes
B. Venkateswara Reddyet al ISSN:2347-4742 JPBMAL, 2014, Vol.2(1):105-111 Review Article Journal of Pharmaceutical and Biomedical Analysis Letters www.pharmaresearchlibrary.com/jpbmal A Review on Process
More informationIdentification of CPPs based on CQAs & Mechanistic Process & Product Understanding: A Case Study
Identification of CPPs based on CQAs & Mechanistic Process & Product Understanding: A Case Study Ajit S. Narang, Ph.D. Bristol-Myers Squibb, Co. 2 nd FDA/PQRI Conference on Advancing Product Quality Bethesda,
More informationManufacturing Technology Committee Risk Management Working Group Risk Management Case Studies. Case No. RMWG-07. Space
Manufacturing Technology Committee Risk Management Working Group Risk Management Case Studies Case Study Title: Defining Process Design Space Case No. RMWG-07 GMP System Impacted: Introduction / Background
More informationPLANKSTADT EXPERTS TAKING CARE
CordenPharma PLANKSTADT EXPERTS TAKING CARE Our History 1977 - Start of Packaging activities (ICI Pharma) 1980 - Start of Formulation activities (ICI Pharma) 1995 - First Pre-approval Inspection by FDA
More informationPAT and Quality by Design exemplified in a Mock P2 submission for examplain tablets. Part 1: Concept and Principles Part 2: Mock P2 Submission
PAT and Quality by Design exemplified in a Mock P2 submission for examplain tablets Part 1: Concept and Principles Part 2: Mock P2 Submission 1 Part 1 Concept and Principles Introduction Rationale Concept
More informationRoller compactors for the pharmaceutical industry. BT 120 Pharma WP 120 Pharma WP 150 Pharma WP 200 Pharma
Roller compactors for the pharmaceutical industry BT 120 Pharma WP 120 Pharma WP 150 Pharma WP 200 Pharma Roller compactors for the pharmaceutical industry Compaction and granulation in the pharmaceutical
More informationINTRODUCTION TO INDUSTRIAL PHARMACY LAB 1
INTRODUCTION TO INDUSTRIAL PHARMACY LAB 1 LAB INSTRUCTORS: LECT. ANAS T ARIK NAFEA ASSIST. LECT. ZAINAB HASSAN MAHDI Definition of Industrial Pharmacy The conversion of raw materials into certain dosage
More informationApplication of PAT for Tablet Analysis. Case examples from Novartis Lorenz Liesum, Lead PAT Hamburg, 19 th of April 2013
Application of PAT for Tablet Analysis Case examples from Novartis Lorenz Liesum, Lead PAT Hamburg, 19 th of April 2013 Agenda PAT@Novartis Organization Business Drivers and Cases NIR Spectroscopy for
More informationStreamlined Manufacture of Modified Release Matrix Tablets via Direct Compression. Katie Hewlett, Dow Gus LaBella, Colorcon
Streamlined Manufacture of Modified Release Matrix Tablets via Direct Compression Katie Hewlett, Dow Gus LaBella, Colorcon Controlled Release Alliance Unique Together Leading polymer expertise Quality
More informationA Compilation of WHO GMP Audit Points
A Compilation of WHO GMP Audit Points Collected from WHOPIR of 28 companies Part III of VIII Current article Part III Production Prepared and Submitted By: Edited by : A. Jwalakanth B.Pharm, MBA (Aus)
More informationMalukani et al., IJPSR, 2012; Vol. 3(7): ISSN:
IJPSR (2012), Vol. 3, Issue 07 (Research Article) Received on 27 March, 2012; received in revised form 17 June, 2012; accepted 25 June, 2012 PROCESS VALIDATION OF SOTALOL HYDROCHLORIDE TABLETS J.N. Malukani*
More informationProcess Validation And Risk Assessment Study of Loratadine Tablet
Vol: 3 Issue: 1 Process Validation And Risk Assessment Study of Loratadine Tablet *1 2 2 2 Vala Khushbu, Patel Chaitali, Rathava Rakesh, Rathod Dhara 1 Department of Pharmaceutical Chemistry, Parul Institute
More informationQuality by Design and Expertise: Accelerating time to market of complex oral solid dosage forms
CPhI Worldwide 2017 October 24 th -v 26 th, 2017 Frankfurt Quality by Design and Expertise: Accelerating time to market of complex oral solid dosage forms Lucile KOWALSKI - NPI Project Manager Guy VERGNAULT
More informationParajuli et al Journal of Drug Delivery & Therapeutics. 2015; 5(6):1-7 1
Parajuli et al Journal of Drug Delivery & Therapeutics. 2015; 5(6):1-7 1 Available online on 15.11.2015 at http://jddtonline.info Journal of Drug Delivery and Therapeutics Open access to Pharmaceutical
More informationPROCESS VALIDATION ROCHAPON WACHAROTAYANKUN, PH.D.
Basic GMP Requirement PROCESS VALIDATION ROCHAPON WACHAROTAYANKUN, PH.D. Topic Process validation What and Why? Principle of process validation Manufacturing process validation Aseptic process validation
More informationISPE Annual Meeting 29 October 1 November 2017 San Diego, CA. FDA Perspective on the Use of Process Capability
FDA Perspective on the Use of Process Capability Chunsheng Cai, Ph.D. Office of Process and Facilities Office of Pharmaceutical Quality, CDER, FDA 2017 ISPE Annual Meeting & Expo Disclaimer This presentation
More informationPREPARATION OF RAW MATERIALS AND SHAPING OF CERAMIC TILES
PREPARATION OF RAW MATERIALS AND SHAPING OF CERAMIC TILES INTRODUCTION: RAW MATERIALS FOR THE PRODUCTION OF CERAMIC TILES Mariano Paganelli FIRST PART: RAW MATERIALS PREPARATION Chapter 1. BODY FORMULATION
More informationIndustry Perspective on Lifecycle Management
Industry Perspective on Lifecycle Management and Post-Approval Building Changes the Best title here Focus on Quality by Design FDA/PQRI Conference on Evolving Product Quality Sep. 16-17, 2014 Michael Kimball
More informationProviding insight into pharmaceutical formulations
Providing insight into pharmaceutical formulations Dr Steve Ward-Smith Pharmaceutical Industry The average cost of developing a drug is reported to be approx $500 million, but up to 70% of new chemical
More informationManaging Quality in Pharmaceutical Industry Using Six Sigma. Edited by Mahmoud Farouk Moussa TQM, CSSBB, MBA
Managing Quality in Pharmaceutical Industry Using Six Sigma Edited by Mahmoud Farouk Moussa TQM, CSSBB, MBA Outlines Pharmaceutical Manufacturing Process and Drug Product Quality. Process Excellence Approach
More informationImplementation of QBD for Analytical Methods - Session Introduction -
Implementation of QBD for Analytical Methods - Session Introduction - Sonja Sekulic January 24, 2014 Quality by Design (QbD) A Systematic Approach ICH Q8(R2) Product Profile Define quality target product
More informationPROCESS VALIDATION OF ZOLPIDEM TARTRATE 5 mg FILM COATED TABLETS
P a g e 68 Asian Journal of PHARMACEUTICAL RESEARCH Journal homepage: - www.ajprjournal.com e-issn 2231 363X Print ISSN 2231 3621 PROCESS VALIDATION OF ZOLPIDEM TARTRATE 5 mg FILM COATED TABLETS Parixit
More informationEngineering in Chemical and Pharmaceutical Processes. Compressing the powder between two surfaces
Engineering in Chemical and Pharmaceutical Processes Particle sizing, Compaction, Extrusion Compaction Dry-granulation Principle Compressing the powder between two surfaces Cohesive forces van der Waals
More informationMeasuring and understanding. of powders with the FT4 Powder Rheometer. freemantechnology
Measuring and understanding of powders with the FT4 Powder Rheometer freemantechnology A universal powder tester The FT4 Powder Rheometer was originally designed to This remains a primary function today,
More informationTABLETABILITY, COMPACTABILITY, AND COMPRESSIBILTY: WHAT S THE DIFFERENCE?
WHITEPAPER TABLETABILITY, COMPACTABILITY, AND COMPRESSIBILTY: WHAT S THE DIFFERENCE? { To patients and consumers, tablets are a simple and convenient dosage form. But the science behind compressing a block
More information7th Training School on Microencapsulation Strasbourg. Februar 2015 Textmasterformat in Mastervorlage eingeben
7th Training School on Microencapsulation Strasbourg Februar 2015 1 Dr. Anne Ettner, Glatt Pharmaceutical Services 2 Overview 1. Introduction 2. Fluid bed equipment 3. Basics of fluid bed Wurster technology
More informationDal Quality by Design alla Process Validation nel processo di sviluppo di un medicinale
Compliance GMP e regolatoria: novità e aggiornamenti MILANO 2 maggio 2018 Dal Quality by Design alla Process Validation nel processo di sviluppo di un medicinale Dr. Maurizio Valleri A.Menarini Manufacturing
More informationPROCESS VALIDATION ANSM 2015 FDA 2011
PROCESS VALIDATION ANSM 2015 FDA 2011 PBE-Expert Inc CANADA Training Company Agreement CPMT #0059104 Qualified Consultant At the measure 2 of the Levier Program PBE, Training Company Agreement CPMT #0059104
More informationAgenda. Applying Quality by Design to Generic Drug Manufacturing. Bikash Chatterjee President & CTO Pharmatech Associates
Applying Quality by Design to Generic Drug Manufacturing Bikash Chatterjee President & CTO Pharmatech Associates 1 Agenda What is QbD? Why it has become important What companies need to know, overview
More informationApproval Application Form for Sakura Bloom Tablets
Approval Application Form for Sakura Bloom Tablets Mock-up for Columns of Manufacturing Methods and Specifications & Test Methods for Drug Products (sample description) Study project for regulatory harmonization
More informationADVANTAGES OF MULTIPARTICULATES (PELLETS):
INTRODUCTION: Multiparticulate Drug Delivery Systems (MDDS): The concept of multiple unit dosage form was initially introduced in the early 1950 s.these forms play a major role in the design of solid dosage
More informationAssociation. Case Study 3. achieving real time release testing by a
Case Study 3 Applying PDA: QbD for A a legacy Global product and achieving real time release testing by a design Association space approach with supportive PAT and soft sensor based models: Challenges
More informationProcess Drift: When Do We Detect it? Richard L. Friedman Director, DMPQ CDER/Office of Compliance PQRI Process Drift Workshop December 1, 2010
Process Drift: When Do We Detect it? Richard L. Friedman Director, DMPQ CDER/Office of Compliance PQRI Process Drift Workshop December 1, 2010 Overview Goal of Manufacturing Central Question: Why is process
More informationPotent Manufacturing of Solid Oral Dosages Utilizing Dry Granulation
Potent Manufacturing of Solid Oral Dosages Utilizing Dry Granulation Shantanu Sonparote AbbVie Associate Process Development Engineer, AbbVie Manufacturing Science & Technology March 18, 2014 Potent Manufacturing
More informationImpact factor: 3.958/ICV: 4.10 ISSN:
Impact factor: 3.958/ICV: 4.10 ISSN: 0976-7908 312 Pharma Science Monitor 9(2),Apr-Jun 2018 PHARMA SCIENCE MONITOR AN INTERNATIONAL JOURNAL OF PHARMACEUTICAL SCIENCES Journal home page: http://www.pharmasm.com
More informationGENERAL GUIDANCE FOR INSPECTORS ON HOLD-TIME STUDIES
July 2013 RESTRICTED 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 GENERAL GUIDANCE FOR INSPECTORS ON HOLD-TIME STUDIES REVISED
More informationAgilent TRS100 Raman. Quantitative Pharmaceutical Analysis System
Agilent TRS100 Raman Quantitative Pharmaceutical Analysis System Agilent TRS100 Raman Streamlined Quality Control Fast Test hundreds of intact tablets or capsules in minutes Simple Quantify active pharmaceutical
More informationContinuous Manufacturing: An Industry View
Novartis Pharmaceuticals Continuous Manufacturing: An Industry View Diane Zezza Novartis Pharmaceuticals FDA/PQRI Conference on Advancing Product Quality March 22, 2017 Where are we today? Continuous Manufacturing
More informationReview Article Review on Quality by Designing for Metered Dose Inhaler Product Development Santosh R. Thorat * 1, Sarika M.
Scholars Academic Journal of Pharmacy (SAJP) Sch. Acad. J. Pharm., 2015; 4(6): 324-330 Scholars Academic and Scientific Publisher (An International Publisher for Academic and Scientific Resources) www.saspublisher.com
More informationSeamless Integration of a Semi- Continuous Coating Process into Existing Solid Dosage Production
Seamless Integration of a Semi- Continuous Coating Process into Existing Solid Dosage Production Abstract A study was conducted using the KOCO 25 in conjunction with the ROB 50, in order to provide insight
More informationParticle Size Reduction MILLING TECHNOLOGY
Material Processing Technologies Pharmaceutical Technologies International, Inc. Princeton, New Jersey, USA Particle Size Reduction MILLING TECHNOLOGY Presented by: Mina Ibrahim, P.Eng., MBA Product Manager,
More informationProduct, Process Knowledge & SPC: PV Lifecycle Approach IFPAC January 2016, Arlington, VA
Product, Process Knowledge & SPC: PV Lifecycle Approach IFPAC January 2016, Arlington, VA Naheed Sayeed Manager, Technical Operations Process Validation, Apotex Inc. 1 Process Validation Life Cycle Stage
More informationFuture of Question-based Review and Regulatory Submissions
Future of Question-based Review and Regulatory Submissions Robert Iser Associate Director for Policy Development (Acting) Office of Pharmaceutical Science / CDER / FDA FDA/PQRI Conference on Evolving Product
More informationFormulation Development & CTM Manufacturing Services
Formulation Development & CTM Manufacturing Services VxP Pharma Purdue Research Park 5225 Exploration Drive Indianapolis, IN 46241 Tel: 317.759.2299 Fax: 317.713.2950 VxP Pharmaprovides an extensive range
More informationMulti Purpose Attachment
oating > Mixing > Grinding > Stirring > Kneading > Granulating > Filling > Homogenising > > Stirring > Kneading > Granulating > Filling > Homogenising > Pelletizing > Sieving > Sha > Dosing > Coating >
More informationAnalytical and formulation attributes
Peer reviewed article Analytical and formulation attributes in developing generic sterile injectable liquid and lyophilized drugs (part 1) Arindam Roy ARINDAM ROY 1,2 *, GURMUKH CHANANA 1 *Corresponding
More informationCOMMON DEFICIENCIES IN FINISHED PHARMACEUTICAL PRODUCT (FPP) DOSSIERS
COMMON DEFICIENCIES IN FINISHED PHARMACEUTICAL PRODUCT (FPP) DOSSIERS Additional guidance for manufacturers This note identifies the most common quality related deficiencies in recently assessed dossiers
More informationProcess Validation Guidelines. Report highlights 23 rd February 2018
Process Validation Guidelines Report highlights 23 rd February 2018 Process validation is an important element of pharmaceutical quality system An effective system provides assurance of the continued capability
More informationSuccessful Tableting Supplement. Continuous Tableting MODUL Q A-Type Tooling. engineering for a better world
Successful Tableting Supplement Continuous Tableting MODUL Q A-Type Tooling engineering for a better world Why GEA? Operational excellence For more than a hundred years, our innovation, driven by our passion
More informationTable Formula of Levodopa + Benserazide HCl capsule (batch no. 004 to 008)
Introduction After using pearlitol SD (200) along with avicel ph 112 the flow of the blend was improved but still not up to the mark. Weight variation was observed around (11.47%) which was not acceptable.
More informationQuality by Design for ANDAs: An Example for Immediate-Release Dosage Forms
Quality by Design for ANDAs: An Example for Immediate-Release Dosage Forms Introduction to the Example This is an example pharmaceutical development report illustrating how ANDA applicants can move toward
More informationImplementation of PAT for Real Time Release Testing. Mark Smith Process Analytical Sciences Group Pfizer, Cork
Implementation of PAT for Real Time Release Testing Mark Smith Process Analytical Sciences Group Pfizer, Cork PAT at Pfizer A key enabler for transformational strategies and new quality paradigms 9 Delivering
More informationOn-Demand Manufacturing of Pharmaceuticals
On-Demand Manufacturing of Pharmaceuticals Innovation in continuous filtration, drying and formulation of drugs International Symposium on Continuous Manufacturing of Pharmaceuticals Salvatore Mascia Sep
More informationFormulation Development Services. Your trust is our reward
Formulation Development Services. Your trust is our reward Index Who we are? Mission and Vision Where we can help you? Infrastructure and Systems Site Plan Services we offer Technologies we practice Quality
More informationCalifornia Grain & Feed Industry Conference Monterey Bay January 16, 2019
California Grain & Feed Industry Conference Monterey Bay January 16, 2019 1 Page 1 Evonik Power to cr Improving Production Efficiency Presented by: Mark Daniel 2 Improving Production Efficiency Combination
More informationPharmaceutical Manufacturing Technology Centre
Pharmaceutical Manufacturing Technology Centre Research themes for Initial Research Programme Call for Proposals The Centre will focus on advanced pharmaceutical manufacturing technologies with an initial
More information